千红制药(002550) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥461,101,487.65, a decrease of 24.19% compared to ¥608,218,905.42 in the same period last year[5] - Net profit attributable to shareholders increased by 21.13% to ¥104,108,160.35 from ¥85,946,847.70 year-on-year[5] - Total operating revenue for Q1 2024 was ¥461.10 million, a decrease of 24.2% compared to ¥608.22 million in the same period last year[19] - Net profit for Q1 2024 was ¥101.35 million, an increase of 21.3% from ¥83.55 million in the previous year[20] - The total comprehensive income for Q1 2024 was ¥100.02 million, compared to ¥83.51 million in the same period last year, marking an increase of 19.8%[22] Cash Flow - The net cash flow from operating activities surged by 709.36% to ¥171,109,914.54, compared to a negative cash flow of ¥28,080,310.76 in the previous year[5] - Cash flow from operating activities generated ¥171.11 million, a significant improvement compared to a negative cash flow of ¥28.08 million in Q1 2023[23] - The net cash flow from investment activities was 81,085,341.57 CNY, a significant improvement compared to -107,460,996.87 CNY in the previous year[24] - The total cash and cash equivalents at the end of the period reached 684,246,877.47 CNY, up from 470,466,348.14 CNY year-over-year[24] - Cash inflow from financing activities was 200,000,000.00 CNY, while cash outflow totaled 140,967,339.59 CNY, resulting in a net cash flow of -140,967,339.59 CNY[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,728,721,168.25, a decrease of 1.35% from ¥2,766,081,444.15 at the end of the previous year[5] - As of March 31, 2024, the total assets amounted to ¥2,728,721,168.25, a decrease from ¥2,766,081,444.15 at the beginning of the period[17] - The total liabilities increased slightly to ¥295,558,850.13 from ¥292,172,947.64[17] - The non-current assets totaled ¥1,149,086,990.33, showing a slight increase from ¥1,140,104,674.78[17] Shareholder Information - Basic earnings per share rose by 23.07% to ¥0.0827 from ¥0.0672 in the same period last year[5] - Earnings per share (EPS) for Q1 2024 was ¥0.0827, up from ¥0.0672 in the same period last year, reflecting a growth of 23.5%[22] - The company completed a share repurchase plan, acquiring a total of 25,000,000 shares, representing 1.95% of the total share capital[14] - The company’s total equity attributable to shareholders was ¥2.42 billion, a slight decrease from ¥2.45 billion year-on-year[21] Operational Efficiency - The company reported a 41.52% decrease in operating costs, primarily due to lower raw material procurement costs compared to the previous year[11] - Total operating costs decreased by 33.4% to ¥344.36 million from ¥517.22 million year-on-year[19] - Research and development expenses were ¥17.48 million, down 15.4% from ¥20.59 million year-on-year, indicating a focus on cost management[19] Other Financial Metrics - The company reported a financial asset fair value change gain of ¥430,734.45, compared to a gain of ¥166,547.42 in the previous year[21] - The company reported a decrease in short-term borrowings to ¥56,213,623.54 from ¥55,622,730.90[17] - The company’s other receivables decreased significantly to ¥4,631,227.88 from ¥16,904,047.16, a decline of approximately 72.6%[15] - Other receivables decreased by 72.6% compared to the beginning of the period, mainly due to compensation received by a subsidiary[11] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[20] Accounting Changes - The company did not undergo an audit for the first quarter report[25] - The company has adopted new accounting standards starting from 2024, affecting the financial statements[25]